Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results

Reuters

2025/06/30

Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results

Cassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2547093296"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547093296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547093296?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547093296","market":"us","top_or_hot":-1,"title":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL7PJhPg:1","article_id":"2547093296","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547093296","pubTimestamp":1751281229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results. Cassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex . The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.Disclaimer: This news brief was created by Public Tec","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","NDAQ":"纳斯达克OMX交易所"},"translate_title":"在取得有希望的临床前结果后，Cassava Sciences宣布计划对Simufilam治疗结节性硬化症相关癫痫进行临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SAVA":0.9},"content_text":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    \n\nCassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}